Literature DB >> 26415647

Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data.

Alexander L Perryman1, Thomas P Stratton2, Sean Ekins3,4, Joel S Freundlich5,6.   

Abstract

PURPOSE: Mouse efficacy studies are a critical hurdle to advance translational research of potential therapeutic compounds for many diseases. Although mouse liver microsomal (MLM) stability studies are not a perfect surrogate for in vivo studies of metabolic clearance, they are the initial model system used to assess metabolic stability. Consequently, we explored the development of machine learning models that can enhance the probability of identifying compounds possessing MLM stability.
METHODS: Published assays on MLM half-life values were identified in PubChem, reformatted, and curated to create a training set with 894 unique small molecules. These data were used to construct machine learning models assessed with internal cross-validation, external tests with a published set of antitubercular compounds, and independent validation with an additional diverse set of 571 compounds (PubChem data on percent metabolism).
RESULTS: "Pruning" out the moderately unstable / moderately stable compounds from the training set produced models with superior predictive power. Bayesian models displayed the best predictive power for identifying compounds with a half-life ≥1 h.
CONCLUSIONS: Our results suggest the pruning strategy may be of general benefit to improve test set enrichment and provide machine learning models with enhanced predictive value for the MLM stability of small organic molecules. This study represents the most exhaustive study to date of using machine learning approaches with MLM data from public sources.

Entities:  

Keywords:  Bayesian model; machine learning; metabolic stability; mouse liver microsomal stability; translational research

Mesh:

Substances:

Year:  2015        PMID: 26415647      PMCID: PMC4712113          DOI: 10.1007/s11095-015-1800-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  88 in total

Review 1.  Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles.

Authors:  D F Lewis
Journal:  Toxicology       Date:  2000-04-03       Impact factor: 4.221

2.  Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.

Authors:  Andreas Bender; Josef Scheiber; Meir Glick; John W Davies; Kamal Azzaoui; Jacques Hamon; Laszlo Urban; Steven Whitebread; Jeremy L Jenkins
Journal:  ChemMedChem       Date:  2007-06       Impact factor: 3.466

3.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

Review 4.  Linear relationships between lipophilic character and biological activity of drugs.

Authors:  C Hansch; W J Dunn
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

Review 5.  Transgenic mouse models of hormonal mammary carcinogenesis: advantages and limitations.

Authors:  Nameer B Kirma; Rajeshwar R Tekmal
Journal:  J Steroid Biochem Mol Biol       Date:  2011-11-17       Impact factor: 4.292

6.  A collaborative database and computational models for tuberculosis drug discovery.

Authors:  Sean Ekins; Justin Bradford; Krishna Dole; Anna Spektor; Kellan Gregory; David Blondeau; Moses Hohman; Barry A Bunin
Journal:  Mol Biosyst       Date:  2010-02-09

Review 7.  Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Authors:  Scott G Franzblau; Mary Ann DeGroote; Sang Hyun Cho; Koen Andries; Eric Nuermberger; Ian M Orme; Khisimuzi Mdluli; Iñigo Angulo-Barturen; Thomas Dick; Veronique Dartois; Anne J Lenaerts
Journal:  Tuberculosis (Edinb)       Date:  2012-08-30       Impact factor: 3.131

8.  PubChem's BioAssay Database.

Authors:  Yanli Wang; Jewen Xiao; Tugba O Suzek; Jian Zhang; Jiyao Wang; Zhigang Zhou; Lianyi Han; Karen Karapetyan; Svetlana Dracheva; Benjamin A Shoemaker; Evan Bolton; Asta Gindulyte; Stephen H Bryant
Journal:  Nucleic Acids Res       Date:  2011-12-02       Impact factor: 16.971

Review 9.  MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.

Authors:  Jennifer P Morton; Owen J Sansom
Journal:  Mol Oncol       Date:  2013-03-08       Impact factor: 6.603

View more
  20 in total

1.  Naïve Bayesian Models for Vero Cell Cytotoxicity.

Authors:  Alexander L Perryman; Jimmy S Patel; Riccardo Russo; Eric Singleton; Nancy Connell; Sean Ekins; Joel S Freundlich
Journal:  Pharm Res       Date:  2018-06-29       Impact factor: 4.200

2.  Machine Learning Platform to Discover Novel Growth Inhibitors of Neisseria gonorrhoeae.

Authors:  Janaina Cruz Pereira; Samer S Daher; Kimberley M Zorn; Matthew Sherwood; Riccardo Russo; Alexander L Perryman; Xin Wang; Madeleine J Freundlich; Sean Ekins; Joel S Freundlich
Journal:  Pharm Res       Date:  2020-07-13       Impact factor: 4.200

3.  Addressing the Metabolic Stability of Antituberculars through Machine Learning.

Authors:  Thomas P Stratton; Alexander L Perryman; Catherine Vilchèze; Riccardo Russo; Shao-Gang Li; Jimmy S Patel; Eric Singleton; Sean Ekins; Nancy Connell; William R Jacobs; Joel S Freundlich
Journal:  ACS Med Chem Lett       Date:  2017-09-14       Impact factor: 4.345

Review 4.  Collaborative drug discovery for More Medicines for Tuberculosis (MM4TB).

Authors:  Sean Ekins; Anna Coulon Spektor; Alex M Clark; Krishna Dole; Barry A Bunin
Journal:  Drug Discov Today       Date:  2016-11-22       Impact factor: 7.851

5.  A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules.

Authors:  Kimberley M Zorn; Shengxi Sun; Cecelia L McConnon; Kelley Ma; Eric K Chen; Daniel H Foil; Thomas R Lane; Lawrence J Liu; Nelly El-Sakkary; Danielle E Skinner; Sean Ekins; Conor R Caffrey
Journal:  ACS Infect Dis       Date:  2021-01-12       Impact factor: 5.084

Review 6.  The Next Era: Deep Learning in Pharmaceutical Research.

Authors:  Sean Ekins
Journal:  Pharm Res       Date:  2016-09-06       Impact factor: 4.200

7.  Data Mining and Computational Modeling of High-Throughput Screening Datasets.

Authors:  Sean Ekins; Alex M Clark; Krishna Dole; Kellan Gregory; Andrew M Mcnutt; Anna Coulon Spektor; Charlie Weatherall; Nadia K Litterman; Barry A Bunin
Journal:  Methods Mol Biol       Date:  2018

8.  Comparison of Deep Learning With Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets.

Authors:  Alexandru Korotcov; Valery Tkachenko; Daniel P Russo; Sean Ekins
Journal:  Mol Pharm       Date:  2017-11-13       Impact factor: 4.939

9.  Exploiting machine learning for end-to-end drug discovery and development.

Authors:  Sean Ekins; Ana C Puhl; Kimberley M Zorn; Thomas R Lane; Daniel P Russo; Jennifer J Klein; Anthony J Hickey; Alex M Clark
Journal:  Nat Mater       Date:  2019-04-18       Impact factor: 43.841

Review 10.  Learning from the past for TB drug discovery in the future.

Authors:  Katarína Mikušová; Sean Ekins
Journal:  Drug Discov Today       Date:  2016-10-04       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.